Business Wire

Business Figures for the First Half of 2018: Sartorius Records Double-Digit Sales Growth

Del

Sartorius, a leading international partner of the biopharmaceutical industry and the research sector, continued on the growth track, with significant increases in sales revenue and earnings. “The first half of 2018 was very successful overall for Sartorius,” commented CEO Joachim Kreuzburg on the results after six months. “We grew dynamically in our two divisions and in all regions and, despite currency headwinds, further increased our profit margin. Due to the dynamics that were slightly above our expectations in Bioprocess Solutions, we have raised our sales forecast for this division and thus for the entire Group.”

Business development of the Sartorius Group

In the first half of 2018, Sartorius increased its sales revenue by 11.9% (reported: +8.0%) in constant currencies to 758.4 million euros. Acquisitions contributed around 2 percentage points to this positive business performance. Order intake rose somewhat more strongly than sales revenue and was up 12.7% (reported: +8.9%).

Regionally, the Americas recorded the highest dynamics. Sales in this region were up 16.6% to 249.6 million euros, relative to a moderate revenue base in the previous year. In Asia|Pacific, Sartorius also grew by double digits, with sales up 12.2% to 184.4 million euros, while the company achieved higher revenue in the EMEA2) region, recording 324.4 million euros, 8.4% up from the comparable period a year ago (regional growth rates in constant currencies).

Earnings also increased robustly: Underlying EBITDA rose 9.6% to 189.5 million euros, despite negative currency effects that occurred especially in the first quarter. The Group’s underlying EBITDA margin improved to 25.0% compared with 24.6% a year ago. Relevant net profit3) for the Group grew even more significantly, by 14.1% from 69.9 million euros to 79.8 million euros. This corresponds to earnings per ordinary share of 1.16 euros (H1 2017: 1.02 euros) and per preference share of 1.17 euros (H1 2017: 1.03 euros).

The Group's key financial indicators continued to remain at robust levels. At the end of the reporting period, the company's equity ratio was 34.9% and its ratio of net debt to underlying EBITDA1) stood at 2.6 (Dec. 31, 2017: 35.1% and 2.5, respectively). The first-half capex ratio was 13.2%, approximately at the previous year’s level and thus within the planned range. Investment activities continued to focus on expansion of the plant for manufacturing single-use bags and filters in Puerto Rico, as well as on the combination and expansion of Group headquarters and production capacity levels in Göttingen, Germany.

As of the reporting date on June 30, 2018, Sartorius employed 7,738 people worldwide, 237 more than as of December 31, 2017 (approx. +3%).

Business development of the divisions

The Bioprocess Solutions Division, which offers a wide array of innovative technologies for the manufacturing of biopharmaceuticals, recorded sales growth of 11.9% in constant currencies to 550.3 million euros (reported: +7.9%) after dynamic business performance in the second half. Consolidation of Umetrics acquired in the previous year contributed close to one percentage point of non-organic growth to sales expansion. Order intake also rose slightly more strongly than expected, up 12.6% in constant currencies (reported: +8.7%).

Underlying EBITDA for the division increased by 10.0% to 153.9 million euros due to economies of scale and despite negative currency effects. The division's corresponding margin was 28.0% relative to 27.4% in the prior-year period.

The Lab Products & Services Division, which offers products and technologies for laboratories primarily in the pharma sector and for life science research, grew by double digits, with sales up 12.0% in constant currencies (reported: +8.1%) to 208.1 million euros. While the division’s organic growth was around 7%, the prior-year acquisition of Essen BioScience, a specialist in cell analysis, contributed non-organic growth of around 5 percentage points. First-half order intake for the division was up 13.1% in constant currencies (reported: +9.2%).

Recording a gain of 7.8%, Lab Products & Services increased its underlying EBITDA from 33.0 million euros to 35.5 million euros. Within the context of the less favorable currency environment its margin remained at the prior-year figure of 17.1%.

Forecast for the full year of 2018 raised

In view of strong business performance in the first half of 2018, management has raised its sales forecast for the Bioprocess Solutions Division and thus for the entire Group. Consolidated sales revenue is projected to grow by about 12% to 15% (previous guidance: 9% to 12%). The Group’s underlying EBITDA margin is still expected to increase by 0.5 percentage points compared with the year-earlier figure of 25.1%.

Given the dynamic growth of sales revenue and order intake in the first half for the Bioprocess Solutions Division, management now projects that division sales will increase by about 12% to 15% (previous guidance about 8% to 11%). This figure includes a non-organic growth contribution of slightly less than 0.5 percentage points. The division's underlying EBITDA margin is forecasted to gain about half a percentage point over the prior-year figure of 28.0%.

For the Lab Products & Services Division, guidance remains unchanged. Sartorius expects division sales to grow by about 12% to 15%, which includes more than 2.5 percentage points of non-organic growth expected to be contributed by Essen BioScience that was consolidated as of the end of March in 2017. The division’s underlying EBITDA margin is projected to rise by around one percentage point (previous year: 18.0%).

All forecasts are based on constant currencies. Due to the latest foreign exchange developments, our results reported in actual currencies may differ. We will explain any particular effects that occur during 2018.

1) Sartorius uses underlying EBITDA (earnings before interest, taxes, depreciation and amortization; adjusted for extraordinary items) as the key profitability indicator
2) EMEA = Europe | Middle East | Africa
3) After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and corresponding tax effects.

This press release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.

Current image files

Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius AG
www.sartorius.com/fileadmin/media/global/company/Sartorius_Kreuzburg.jpg

Sartorius products used in the manufacture of medications
https://www.sartorius.com/mediafile/corp/Sartorius_0232_PG9_01_RGB.jpg

Sartorius products used in pharmaceutical research
www.sartorius.com/mediafile/corp/Sartorius_0424_PG14.jpg

Conference call

Joachim Kreuzburg, CEO and Executive Board Chairman of Sartorius, and Rainer Lehmann, CFO of Sartorius, will discuss the company's business results with analysts and investors on Tuesday, July 24, 2018, at 3:30 p.m. Central European Time (CET) in a teleconference. You may register by clicking on the following link:
http://services.choruscall.de/DiamondPassRegistration/register?confirmationNumber=2924053&linkSecurityString=122e29ee9

Alternatively, you can dial into the teleconference, without registering, at:
+49 (0) 69 566 03 6000

The company presentation will be available on July 24, 2018, starting at 3:15 p.m. CET, for viewing on our website at:
http://www.sartorius.com/com/group/investor-relations/sartorius-ag/

Upcoming financial date:

October 23, 2018 Publication of nine-month figures (January to September 2018)

A profile of Sartorius

The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than 1.4 billion euros in 2017. More than 7,500 people work at the Group's approximately 50 manufacturing and sales sites, serving customers around the globe.

Key Figures for the First Half of 2018

             
Sartorius Group Bioprocess Solutions Lab Products & Services
In millions of € (unless otherwise specified)      

H1
2018

    H1
20175)
   

Δ∆ in %
Reported

   

Δ∆ in %
cc1)

    H1
2018
    H1
20175)
   

Δ∆ in %
Reported

     

Δ∆ in %
cc1)

    H1
2018
    H1
20175)
   

Δ∆ in %
Reported

   

Δ∆ in %
cc1)

Sales Revenue and Order Intake
Sales revenue       758.4     702.5     8.0     11,9     550.3     510.1     7.9       11,9     208.1     192.4     8.1     12.0

- EMEA2)

      324.4     301.8     7.5     8,4     229.5     208.5     10.0       10,7     94.9     93.3     1.8     3.3
- Americas2)       249.6     228.5     9.3     16,6     195.8     181.3     8.0       15,4     53.9     47.2     14.1     20.9
- Asia | Pacific2)       184.4     172.2     7.1     12,2     125.1     120.3     4.0       8,9     59.3     51.9     14.2     19.9
Order intake       807.6     741.9     8.9     12,7     594.6     546.9     8.7       12,6     213.0     195.0     9.2     13.1
Earnings
EBITDA3)       189.5     172.9     9.6           153.9     140.0     10.0             35.5     33.0     7.8      
EBITDA margin3) in %       25.0     24.6                 28.0     27.4                   17.1     17.1            
Net profit for the period4)       79.8     69.9     14.1                                                        
Financial Data per Share

Earnings per ordinary share4) in €

      1.16     1.02     14.1                                                        

Earnings per preference share4) in €

      1.17     1.03     14.0                                                        
 

1) In constant currencies

2) Acc. to the customer’s location

3) Adjusted for extraordinary items

4) After non-controlling interest, adjusted for extraordinary items and non-cash amortization, as well as based on the normalized financial result and corresponding tax effects

5) The previous year's figures have been restated due to the finalization of the purchase price allocations for the acquisitions of 2017

 

Contact information

Sartorius AG
Petra Kirchhoff, +49 (0)551.308.1686
Head of Corporate Communications
petra.kirchhoff@sartorius.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Three Finalists Selected Following GA-ASI’s Blue Magic Belgium Event15.6.2019 11:00:00 CESTPressemelding

Three finalists have been selected from GA-ASI’s Blue Magic Belgium event with the goal of supporting GA-ASI and the development of MQ-9B SkyGuardian Remotely Piloted Aircraft (RPA) for Belgium. The three Belgian companies selected are AIRobot, ALX Systems, and Hexagon. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190615005003/en/ "We were very impressed by the many talented companies and particularly by the innovative concepts presented by these three finalists," said Linden Blue, CEO, GA-ASI. (Photo: Business Wire) AIRobot, a company based at DronePort in Sint Truiden, Belgium, focuses on developing drone performance equipment for easy, precise and safe professional operations, while specializing in Artificial Intelligence (AI) for processing hyper-spectral imagery. ALX Systems is an Unmanned Aircraft System (UAS) solution provider based in Liège, Belgium and specializing in AI for processing Full Motion Video. Hexagon’s

World’s First E-Money License for Blockchains Issued to Monerium15.6.2019 08:35:00 CESTPressemelding

Monerium ehf. has received a license from the Financial Supervisory Authority of Iceland to issue e-money on blockchains through its subsidiary, Monerium EMI ehf. The full license is the world’s first e-money license for blockchains issued under EU e-money regulations. The license is passportable within the largest global economic zone, the European Economic Area, and to external jurisdictions subject to regulatory approval and destination country regulations. Designed as a digital alternative to cash, e-money is a proven framework for digital fiat currency already in use for pre-paid cards and mobile wallets. By issuing e-money on blockchains, Monerium removes the need for intermediaries and provides the ability to automate financial transactions in many sectors, including payments, trade finance, securities settlement, and ecommerce. At the same time, e-money on blockchains extends Satoshi Nakamoto’s vision of online peer-to-peer currency transactions to a regulated form of digital f

Mattel® Unveils Hot Wheels™ id, Groundbreaking New Play System Bringing Together Physical and Digital Play, Available Exclusively at Apple.com, Select Apple Stores and on the App Store14.6.2019 13:00:00 CESTPressemelding

Mattel, Inc. (NASDAQ: MAT) today announced the launch of Hot Wheels id, the evolution of the beloved brand that generations of kids have played with to ignite their challenger spirit. Through innovative vehicle play, Hot Wheels id brings together physical and digital in a Mixed Play experience with uniquely identifiable vehicles, a smart Race Portal, Smart Track, and digital hub, so you can build your personalized fleet, measure your performance, and compete like never before. Hot Wheels id is available starting June 14th exclusively at Apple.com, select Apple stores and on the App Store. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190614005084/en/ Hot Wheels Race Portal™ scans your Hot Wheels id vehicles into the app, tracks speed and counts laps via infrared sensors, and easily connects with your classic Hot Wheels track. (Photo: Business Wire) For the first time in history, kids can scan their Hot Wheels id cars digita

S BLOCK Co-host With World Blockchain Forum Singapore & World Blockchain Award Asia14.6.2019 12:45:00 CESTPressemelding

Asia's highly anticipated blockchain event World Blockchain Forum · Singapore & World Blockchain Award · Asia will be held on June 22-23, 2019 at the Marina Bay Sands in Singapore. The conference will bring together more than 4,000 global elites from government, associations, regulatory agencies, investment institutions, blockchain project parties, financial technology, and media to discuss industry trends and innovations, jointly recognizing industry pioneers and contributions to promote the industry and achieve healthy and rapid development! The World Blockchain Forum Singapore & World Blockchain Award Asia will be co-hosted by S BLOCK. As a fast-growing digital asset management platform, S BLOCK was developed for the blockchain industry. This rapidly growing platform aims to serve the digital financial ecosystem and aims to commercialize by the end of 2019. The slogan of S BLOCK is “unleash your digital asset.” The platform also provides investors access to mainstream cryptocurrenci

Janssen Reports Top-Line Phase 3 Results for TREMFYA® (guselkumab) in Adults with Active Psoriatic Arthritis14.6.2019 11:39:00 CESTPressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced top-line results from the Phase 3 DISCOVER 1 and 2 studies, which evaluated the efficacy and safety of guselkumab compared to placebo in adult patients with active moderate to severe psoriatic arthritis (PsA). Both studies met their primary endpoints of American College of Rheumatology 20% improvement (ACR20), and the safety profiles observed for guselkumab in the DISCOVER programme were consistent with previous studies of guselkumab and current prescribing information.1 The DISCOVER programme comprises the first-ever Phase 3 studies evaluating an IL-23 p19 inhibitor for the treatment of psoriatic arthritis, and data will be presented at upcoming scientific medical meetings. Data from the two DISCOVER studies will serve as the basis of submissions to the U.S. Food and Drug Administration and European Medicines Agency seeking approval of guselkumab as a treatment for psoriatic arthritis, which are anticipated for

Velodyne Features Advanced Lidar for Port Terminal Automation at TOC Europe14.6.2019 10:00:00 CESTPressemelding

Velodyne Lidar, Inc. (Stand A50) will demonstrate how its smart, powerful lidar solutions can advance port terminal automation at TOC Europe in Rotterdam, 18-20 June. Velodyne will highlight customer applications that show how its lidar sensors can be used in crane steering, container handling, internal terminal vehicles (ITV), automated guided vehicles (AGV), forklifts, and terminal security/yard monitoring systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190614005040/en/ DGWorld solutions demonstrate how Velodyne’s intelligent lidar sensors are helping port and terminal operators deliver consistent service quality and achieve increased safety. (Photo: Business Wire) DGWorld (Stand B21A), a Dubai-based Velodyne integrator, will showcase autonomous taxis, ITVs, AGVs, and terminal operation vehicles that use Velodyne lidar sensors to run autonomously. These vehicles use advanced artificial intelligence (AI), automation